Goeltz II Robert C. 4
4 · Arcus Biosciences, Inc. · Filed Jan 25, 2023
Insider Transaction Report
Form 4
Goeltz II Robert C.
Chief Financial Officer
Transactions
- Award
Common Stock
2023-01-23+34,000→ 63,441 total - Award
Stock Option (right to buy)
2023-01-23+138,200→ 138,200 totalExercise: $22.02Exp: 2033-01-22→ Common Stock (138,200 underlying)
Footnotes (2)
- [F1]Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2023, subject to the Reporting Person's continued service to the Company.
- [F2]The option becomes exercisable in 48 equal monthly installments after January 1, 2023, subject to the Reporting Person's continued service to the Company.